Role of gastric mucosal barrier dysfunction during gastric carcinogenesis after H.pylori eradication

Role of gastric mucosal barrier dysfunction during gastric carcinogenesis after H.pylori eradication - Mucosal barrier dysfunction during gastric carcinogenesis after H.pylori eradication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028641

Enrollment

Registered

2017-09-22

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer after successful eradication

Interventions

endoscopic biopsy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with follow-up endoscopic examination after ESD for post-eradication gastric cancer

Exclusion criteria

Exclusion criteria: 1. contraindication for endoscoic biopsy 2. patients who take NSAIDs, steroid, or immunosuppressive medication 3. patients treated by surgecy for upper GI tract 4. patients who take antibiotics in 12 months 5. pregnancy 6. severe general condition or phycological dysorder 7. inappropriate for enrolling this trial

Design outcomes

Primary

Measure	Time frame
Difference in mucosal barrier dysfunction caused by acetaldehyde or peptideglycan	—

Countries

Japan

Contacts

Public ContactKaname Uno

Tohoku university Gastroenterology

kaname-1@umin.ac.jp022-717-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026